Cellectis(CLLS) - 2021 Q4 - Annual Report

EXHIBIT 99.1 Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track for planned 2022 IND submission for UCART20x22, our first allogeneic dual CAR T-cell product candidate, in B-cell non-Hodgkin's Lymphoma Two manufacturing sites are now fully operational; ...